Methods. This was a prospective case series to identify risk factors for HAART nonadherence among 43 patients with HIV and tuberculosis (TB) in Lima, Peru. Nonadherence was defined by patient self-report. Results. The median initial CD4 and HIV viral load were 63 and 159,000, respectively. Patients had received a median of 6.1 months of ART. Univariable analysis found low social support, substance use, and depression to be associated with nonadherence. In multivariable analysis, low social support was associated with nonadherence. Conclusions. In the authors' urban cohort of HIV-TB coinfected individuals in Lima, Peru, substance use, depression, and lack of social support were key barriers to adherence. These findings suggest that adherence interventions may be unsuccessful unless they target the underlying psychosocial challenges faced by patients living with TB and AIDS.
Human immunodeficiency virus (HIV) and tuberculosis (TB) are disproportionately diseases of the poor. 1 Hunger, limited economic sovereignty, and discrimination increase the risk of HIV and TB infection among poor men and women. [2] [3] [4] [5] [6] [7] [8] [9] Once infected, these same factors contribute to excess mortality and morbidity experienced by poor individuals living in both developed and developing countries. A myriad of challenges-such as difficulty accessing health services, food insecurity, depression, lack of social support, and stigma-exacerbate the stress of living with HIV and place poor individuals at increased risk of nonadherence to highly active antiretroviral therapy (HAART) and poor clinical outcomes. [10] [11] [12] [13] [14] [15] [16] In the Unites States, low social support, depression, substance use, and lower socioeconomic level have all been associated with HAART nonadherence, in particular, among poor populations. [17] [18] [19] [20] [21] Data supporting the impact of psychosocial factors on HAART adherence in resource-poor settings are scarce. Nemes et al found that illiteracy predicted nonadherence among Brazilian patients, 22 whereas a study by Pinheiro et al in Southern Brazil identified self-efficacy and level of education as predictors of nonadherence. 23 Another study in Venezuela reported that HAART use was associated with availability of social support. 24 Finally, in a population of Senegalese patients, nonadherence to TB prophylaxis treatment was associated with low social support, lack of money for food and transport, and fear of stigmatization. 25 For individuals with TB and HIV, the combined complexities of adherence are poorly understood. On one hand, the unstable socioeconomic environment that places these patients at risk of contracting both diseases may pose greater challenges to adherence, in particular, to life-long HAART. The additional physical and emotional toll of dual infections-including a heightened fear of death given high mortality among such cases-could have a potential positive or negative impact on adherence. Finally, TB treatment in resource-poor settings is often administered through DOTS (World Health Organization, Stop TB Strategy), providing structured supervision and activities directed at case holding. 26 Although the additional pill burden of simultaneous TB and HIV treatment may exacerbate Psychosocial Impact of Poverty on Antiretroviral Nonadherence in Lima, Peru medication intolerance, the potential to integrate HAART initiation into the DOTS process is an opportunity that merits exploration. [27] [28] [29] Given the scarcity of knowledge on factors shaping HAART adherence in resource-poor settings, we sought to characterize a cohort of patients with HIV-TB coinfection in Lima, Peru. We hypothesized this population would be characterized by socioeconomic hardship and a high degree of psychosocial stress and that these difficulties would, in turn, influence a patient's ability to adhere to antiretroviral treatment.
Methods

Study Setting
Peru has a relatively low HIV prevalence, with an estimated 93 000 individuals (0.6%) living with HIV. 30 Although 65% of the HIV-infected population resides in Lima, 31 emerging data of remote communities with high rates of HIV 32 likely reflect current underestimates of the Peruvian HIV epidemic. Eighty percent of AIDS cases notified between 1983 and 2005 were male, and most were older than 30 years of age. 31 The Peruvian National HIV Program was established in 1994. Large-scale provision of free antiretroviral therapy was not possible until financial support through the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) was obtained in 2004. 33 Currently, more than 9000 individuals are taking HAART, 6137 of whom are supported by the Ministry of Health HIV Program (J L Sebastian, Peruvian National HIV Program, personal e-mail communication, April 25, 2007) . All patients meeting these criteria were successively identified and referred by Ministry of Health HIV providers. All referred individuals signed informed consent to participate in this study.
Sample
Instruments
Psychosocial assessments covered depression, social support, quality of life, and stigma. All instruments were initially piloted with 8 HIV-positive individuals, and then reviewed with the entire study team to modify wording to ensure that the questions were understood by this population.
To assess depression, we used the Hopkins Symptom Checklist-15. [34] [35] [36] This 15-item questionnaire has demonstrated adequate performance in assessing depression in HIV-positive individuals, and in multicultural populations, although it may have limitations in identifying severity of depressive symptoms in certain populations. [37] [38] [39] [40] Questions are scored on a severity scale from 1 (para nada) to 4 (mucho), with a higher score indicating more depressive symptoms.
We used the Duke University of North Carolina Functional Social Support Questionnaire to assess perceived social support. 41 This is a 10-item scale that assesses emotional/affective as well as material/ instrumental support. As with Kaaya et al, 38 we opted to use the scale that included 2 items that were excluded in the original derivation: "help with transportation" and "help with money" because of the importance of such forms of support in our population. Questions in this instrument were scored on a 4-point severity scale, ranging from 0 (nunca) to 4 (mucho); a low score correlated with low social support. This instrument has been used with HIV-positive patients 42 and has been validated in Spanish. 43 The Medical Outcomes Study HIV Health Survey (MOS-HIV) was administered to assess quality of life. 44 This is a 35-item questionnaire with 10 dimensions (general health perceptions, pain, physical functioning, role functioning, social functioning, cognitive functioning, mental health, energy/fatigue, health distress, and quality of life). Subscales and summary scores are rated on a 0-100 scale, with higher scores indicating better health. This instrument's internal consistency and responsiveness to change over time has been widely demonstrated in a variety of HIVpositive populations, 45 including in Spanish-speaking populations. 46 The Berger Stigma Instrument was developed to measure perceived stigma among HIV-positive individuals. 47 This is a 40-item questionnaire scored on a 4-point Likert-type scale, with higher scores reflecting greater perceived stigma. Four factors have been described: personalized stigma, disclosure concerns, negative self-image, and concern with public attitudes toward people with HIV. Because we found no published reports of a Spanish version of this instrument, an individual fluent in both Spanish and English translated the questionnaire into Spanish. The instrument was then back-translated to English by another bilingual individual. The Spanish translation was then reviewed by Peruvian health providers and lay individuals to ensure that the conceptual meaning of each question was preserved in the Peruvian-Spanish version. The instrument was finalized after piloting with several patients with HIV to ensure that the questions and language were understood by the study population.
Additional psychosocial data included information on alcohol and substance use, ability to access health services, perceived benefit of HAART, and selfefficacy. For the latter 3 themes, we derived our questions by adapting an instrument used by our "sister-organization," PACT, which provides outreach to HIV patients, including Spanish-speaking ones, in Boston. 48 We included 8 questions regarding access and utilization of health services, adapted from the Health Care Services and Utilization Study (HCSUS) study, 49 as well as 7 questions exploring patients' perceptions of the utility of HAART and possible reasons why they may choose not to take their medications. Finally, we utilized an 8-item questionnaire on selfefficacy that was developed by PACT, which evaluates the patients' confidence in their ability to take HAART, access health services, and communicate with providers. This questionnaire draws from the HIV Self-Efficacy questionnaire, 50 as well as the Confidence in Diabetes Self-Care Scale 51 and HIV self-management items developed and tested by Smith and colleagues 52 specific to medication adherence.
HAART nonadherence was based on patient selfreport, which has been shown to have acceptable reliability in patients in resource-poor settings. 53 We defined HAART nonadherence as having missed any dose of antiretroviral treatment in the past 4 weeks, per patient report.
Data Collection
Baseline data were collected within 1 month of enrollment into the study. Socioeconomic and clinical data were collected using standardized forms, based on patient interview and chart review. Psychosocial data were obtained in a series of 3 one-on-one interviews, conducted at the patient's home (or in an alternative site, if specified by the patient). Interviews were all verbally administered, given some participants were illiterate. Interviewers were trained in the administration of all instruments. Quality control was performed on all forms, including comparison of data with patient charts, interview observation by a research assistant, and confirmation of outlying, inconsistent, or missing data. All data were entered into an ACCESS database (Microsoft, Seattle, Washington).
Analysis
We performed a summary description of demographic, clinical, and psychosocial characteristics of patients, by inclusion criteria. We assessed the internal consistency reliability of each instrument using the Cronbach's alpha; for all instruments, the Cronbach's alpha was ≥.80. We assessed the association between baseline clinical and psychosocial characteristics with HAART nonadherence. Analysis was conducted using SAS Version 9.1 (SAS Institute, Inc, Cary, North Carolina). Univariate and multiple logistic regression models were used to generate effect estimates of the association between patient characteristics and nonadherence. Variables included in univariate analysis were chosen based on existing scientific literature and our hypothesis that psychosocial stressors, in particular, lack of social support, were linked to nonadherence. Noncollinear variables associated with nonadherence in the univariate analysis (P value < .05) were entered into a multivariable analysis. For variables in which we postulated that effect modification could be present, we assessed for and did not detect effect modification.
This protocol was approved by the Partners Human Subjects Committee at the Brigham and Women's Hospital, both hospitals' ethics committees, and that of the Peruvian National Institute of Health.
Results
There were 43 patients in the cohort. Patients had a median of 6.1 months (range, 0.07-16.8) on TB treatment and a median of 2.4 months (range, 0.6-11.5) on HAART at the time of interviews. Baseline sociodemographic and clinical characteristics are summarized in Table 1 . The majority of patients were unemployed, living in poor, crowded conditions. More than half of patients reported food scarcity, that is, having gone at least a day without eating due to economic hardship. In general, patients were recently diagnosed with HIV (median and range of years since HIV diagnosis of 0.6, 0.02-9.0) and had presented with advanced AIDS. Sixteen patients (37.2%) reported HAART nonadherence in the past month.
The cohort was characterized by poor psychosocial well-being, based on the Hopkins' Symptom Checklist and MOS-HIV Quality of Life scores. Although a cutoff score for the Hopkins' Symptom Checklist was not validated in this cohort, based on a cutoff of 1.75, 54, 55 almost half of the cohort had symptoms consistent with major depression. In addition, because the MOS-HIV Quality of Life instrument has been validated across languages and cultures, we compared our scores with other cohorts. As shown in Table 2 , mean scores in our cohort tended to be low, compared with other cohorts Psychosocial Impact of Poverty on Antiretroviral Nonadherence in Lima, Peru of AIDS patients, including those speaking Spanish and living in poverty (in the United States and in developing countries).
We performed a univariate analysis to identify factors associated with nonadherence to HAART. As shown in Table 3 , low social support, depression, and substance use were associated with HAART nonadherence. Low social support remained significantly associated with nonadherence in a multivariable analysis, as shown in Table 4 .
Discussion
In resource-poor settings, the impact of poverty on individual behavior and health service infrastructure can profoundly limit the patient's ability to adhere to HAART. [56] [57] [58] For patients who are unable to travel to the nearest HIV treatment site to pick up medications, eat food prior to taking HAART to avoid intolerance, or disclose one's status to a sexual partner who provides financial support, adherence may not be a choice, but simply not an option, despite the desire to adhere and a thorough understanding of the consequences of not doing so. [59] [60] [61] The greater the structural barriers, the more vulnerable a patient is to the destabilizing effects of psychosocial stressors. 62, 63 These stressors, in turn, further limit the patient's ability to adhere to treatment. 64 
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Our study reports on a cohort of impoverished HIV-TB coinfected individuals in Lima, Peru. These patients had recently started TB treatment and, on average 2 months later, initiated HAART. Most were recently diagnosed with HIV and had presented with advanced AIDS. Patients in this cohort reported poor quality of life and high rates of depressive symptomatology. The poor psychosocial status of our cohort was notable in several respects. First, physicians identified fewer than half of those meeting criteria for major depression by the Hopkins' Symptom Checklist. Although the discrepancy between rates of depression measured could be due to poor calibration of the cutoff score for our population, we feel this is unlikely because rates of depression based on this cut-off declined from 56.7% to 4.2% in a subgroup of individuals who were provided a year of psychosocial support. 65 Furthermore, almost 20% had experienced suicidal ideation in the past month, but only 2 had reported these thoughts to their physicians. These findings highlight the severity of mental health disorders in this population. Furthermore, overall psychosocial well-being in this cohort is poor and, despite access to HIV and TB services, these mental health needs-some of them critical-are not being met. Such findings highlight the need to integrate mental health and psychosocial care into HIV care.
The implications for providing psychosocial support go beyond mental well-being. We found that low social support was significantly associated with nonadherence. Although not statistically significant, depression and substance use also appeared to impair HAART adherence. Importantly, evidencebased interventions exist for all of these risk factors and could be applied to improve HAART adherence.
We are encouraged by several reports of social support interventions from resource-poor settings. In a qualitative study in South Africa, patients described sources of social support for HAART adherence. During the initial 3 months of HAART, treatment counselors were essential in educating patients about illness management and motivating them to adhere to regimens. However, after the first 3 months, treatment fatigue, physical recovery, and adverse effects emerged to jeopardize adherence. Patients described "treatment supporters" as key providers of emotional support. Supporters were usually a relative or friend identified by the patient to remind and encourage the patient to take HAART. Beyond adherence promotion, treatment supporters were important sources of emotional support for this population, in which rejection and violence were risk factors for nonadherence. Another home-based program in Uganda utilized numerous social support services, including weekly delivery of medications, group education, counselorsupported elaboration of personal adherence plans, and a medication companion; high adherence rates were achieved during the year of support. 66 Malta et al provided an innovative example of outreach for urban injecting drug-users in Rio de Janeiro. 67 The team used mobile case management and peer-based support groups and reported improvements in HAART adherence and perceived social support. In a small cohort from Rwanda, a high level of treatment adherence was achieved with the help of family support and counseling despite the poverty, adverse effects, and severity of disease progression. 68 Similarly, our group has developed an "accompagnateur" model in rural Haiti. 69 Accompagnateurs provide DOT-HAART, not only helping patients overcome daily barriers to pill-taking, but in addition providing emotional and informational support and serving as liaisons with formal health services. 10 In addition to decreasing economic barriers to health care, the "accompagnateur" model has allowed successful scale-up of HIV coverage to more than 2500 patients in rural Haiti and 2000 patients in rural Rwanda with excellent adherence and clinical outcomes. 70 Although this study is limited by a small sample size and the use of patient self-report to measure nonadherence, these findings contribute to the understanding of nonadherence in resource-poor settings. Patients in this cohort reported poor quality of life and severe depressive symptomatology. In this population, mental health pathology is yet another manifestation of poverty, in addition to HIV and TB. Despite successfully accessing HIV and TB care, these patients still receive inadequate care for their overall well-being through the formal health sector. Low social support was associated with nonadherence within the first year of HAART. For patients with TB and HIV coinfection, the infrastructure provided by DOTS for TB treatment offers one possible means for initial adherence support as patients start HAART. Community-based DOT delivers not only logistical support around pill-taking but, in addition, social and emotional support. In resource-poor settings, innovative interventions-such as the examples described above-are sorely needed to address the psychosocial barriers to HAART adherence imposed by poverty. 
